Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis

EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab. Data from 86 patients with a median age of 67 years and a median of two prior lines of treatment were analyzed. Treatment-related adverse events (TRAEs) occurred in 95% of patients. Grade

• Illini, O.
• Saalfeld, F. C.
• Christopoulos, P.
• Duruisseaux, M.
• Vikström, A.
• Peled, N.
• Demedts, I.
• Dudnik, E.
• Eisert, A.
• Hashemi, S. M. S.
• Janzic, U.
• Kian, W.
• Mohorcic, K.
• Mohammed, S.
• Silvoniemi, M.
• Rothschild, S. I.
• Schulz, C.
• Wesseler, C.
• Addeo, A.
• Armster, K.
• Itchins, M.
• Ivanovi
• Kauffmann-Guerrero, D.
• Koivunen, J.
• Kuon, J.
• Pavlakis, N.
• Piet, B.
• Sebastian, M.
• Velthaus-Rusik, J. L.
• Wannesson, L.
• Wiesweg, M.
• Wurm, R.
• Albers-Leischner, C.
• Aust, D. E.
• Janning, M.
• Fabikan, H.
• Herold, S.
• Klimova, A.
• Loges, S.
• Sharapova, Y.
• Sch
• Weinlinger, C.
• Valipour, A.
• Overbeck, T. R.
• Griesinger, F.
• Jakopovic, M.
• Hochmair, M. J.
• Wermke, M.